{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:27:34Z","timestamp":1794414454512,"version":"4.9.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Optic nerve imaging assessing papilloedema is an increasingly important clinical measure to guide treatment. The aim of this study was to understand the agreement between two commonly used OCT devices and whether pooling of papilloedema OCT imaging data could be easily facilitated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>People living with idiopathic intracranial hypertension (IIH) underwent non-dilated same-day OCT imaging performed on Spectralis SD-OCT (Heidelberg Engineering, Heidelberg, Germany) and Cirrus 6000 OCT (Carl Zeiss Meditec, Dublin, CA). Comparable measurements were collected (retinal nerve fibre layer (RNFL), maximum height of the optic nerve head and macular ganglion cell layer assessment). Bland-Altman plots were constructed, intraclass correlation coefficient (ICC) and Pearson correlation coefficient were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ninety-seven people with a definite diagnosis of IIH were included: 95% were women with a mean age of 31 years. Mean global RNFL thickness was 117.4\u03bcm (SD 41.6) on the Spectralis platform and 122.5\u03bcm (SD 53.8) on the Cirrus platform. There was excellent agreement between the devices for RNFL thickness measurements (ICC\u2009=\u20090.922), although the Bland-Altman plot revealed increasing discrepancy at higher RNFL thicknesses. Maximum disc height displayed good agreement (ICC\u2009=\u20090.882) between devices. There was a very strong positive correlation between Spectralis GCL volume and Cirrus GC-IPL thickness(r\u2009=\u20090.911).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This OCT imaging dataset spanning a range of papilloedema severity in people with a definite diagnosis of IIH showed good relative agreement of RNFL measurements between Spectralis and Cirrus devices at RNFL thicknesses close to normal, but greater variance with more severe papilloedema. RNFL measurements from the two devices cannot be used interchangeably. Macular GCL assessments showed a strong positive linear correlation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-026-04823-4","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:46:39Z","timestamp":1790102799000},"page":"2633-2640","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optical coherence tomography imaging device comparison study in papilloedema secondary to idiopathic intracranial hypertension"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3390-9508","authenticated-orcid":false,"given":"Gabriele","family":"Berman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8905-5734","authenticated-orcid":false,"given":"Andreas","family":"Yiangou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7772-2157","authenticated-orcid":false,"given":"Mark","family":"Thaller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Capewell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Holding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5658-2335","authenticated-orcid":false,"given":"Georgios","family":"Tsermoulas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2777-5132","authenticated-orcid":false,"given":"Alexandra J.","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6142-3280","authenticated-orcid":false,"given":"Richard J.","family":"Blanch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6314-4437","authenticated-orcid":false,"given":"Susan P.","family":"Mollan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"4823_CR1","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.4103\/IJO.IJO_594_24","volume":"72","author":"ST Bassi","year":"2024","unstructured":"Bassi ST, Newman NJ, Chen JJ, Tisavipat NY, Mollan SP, Moss HE, et al. Recent advances in neuro-ophthalmology. Indian J Ophthalmol. 2024;72:1544\u201359. https:\/\/doi.org\/10.4103\/IJO.IJO_594_24.","journal-title":"Indian J Ophthalmol"},{"key":"4823_CR2","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1038\/s41433-024-03165-3","volume":"38","author":"HJ Shin","year":"2024","unstructured":"Shin HJ, Costello F. Imaging the optic nerve with optical coherence tomography. Eye. 2024;38:2365\u201379. https:\/\/doi.org\/10.1038\/s41433-024-03165-3.","journal-title":"Eye"},{"key":"4823_CR3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ajo.2023.01.016","volume":"250","author":"YF Hyder","year":"2023","unstructured":"Hyder YF, Homer V, Thaller M, Byrne M, Tsermoulas G, Piccus R, et al. Defining the phenotype and prognosis of people with idiopathic intracranial hypertension after cerebrospinal fluid diversion surgery. Am J Ophthalmol. 2023;250:70\u201381. https:\/\/doi.org\/10.1016\/j.ajo.2023.01.016.","journal-title":"Am J Ophthalmol"},{"key":"4823_CR4","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s00415-022-11402-6","volume":"270","author":"M Thaller","year":"2023","unstructured":"Thaller M, Homer V, Hyder Y, Yiangou A, Liczkowski A, Fong AW, et al. The idiopathic intracranial hypertension prospective cohort study: evaluation of prognostic factors and outcomes. J Neurol. 2023;270:851\u201363. https:\/\/doi.org\/10.1007\/s00415-022-11402-6.","journal-title":"J Neurol"},{"key":"4823_CR5","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1001\/jamaophthalmol.2020.4242","volume":"138","author":"V Vijay","year":"2020","unstructured":"Vijay V, Mollan SP, Mitchell JL, Bilton E, Alimajstorovic Z, Markey KA, et al. Using optical coherence tomography as a surrogate of measurements of intracranial pressure in idiopathic intracranial hypertension. JAMA Ophthalmol. 2020;138:1264 https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.4242.","journal-title":"JAMA Ophthalmol"},{"key":"4823_CR6","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/ana.25462","volume":"85","author":"RC Nolan-Kenney","year":"2019","unstructured":"Nolan-Kenney RC, Liu M, Akhand O, Calabresi PA, Paul F, Petzold A, et al. Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: an international study. Ann Neurol. 2019;85:618\u201329.","journal-title":"Ann Neurol"},{"key":"4823_CR7","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/WNO.0000000000001717","volume":"42","author":"R Kenney","year":"2022","unstructured":"Kenney R, Liu M, Hasanaj L, Joseph B, Al-Hassan AA, Balk L, et al. Normative data and conversion equation for spectral-domain optical coherence tomography in an international healthy control cohort. J Neuroophthalmol. 2022;42:442\u201353. https:\/\/doi.org\/10.1097\/WNO.0000000000001717.","journal-title":"J Neuroophthalmol"},{"key":"4823_CR8","doi-asserted-by":"publisher","unstructured":"Bacchetti A, McCormack B, Lin TY, Doosti R, Ahmadi G, Ezzedin O, et al. Test\u2013retest reliability of Cirrus HD-optical coherence tomography retinal layer thickness measurements in people with multiple sclerosis. Mult Scler J Exp Transl Clin. 2025;11(2):20552173251340957. https:\/\/doi.org\/10.1177\/20552173251340957.","DOI":"10.1177\/20552173251340957"},{"key":"4823_CR9","unstructured":"Faghihi H, Hajizadeh F, Hashemi H, Khabazkhoob M. Agreement of two different spectral domain optical coherence tomography instruments for retinal nerve fiber layer measurements. J Ophthalmic Vis Res. 2014;9:31\u201337."},{"key":"4823_CR10","doi-asserted-by":"publisher","first-page":"5912","DOI":"10.1167\/iovs.11-8644","volume":"53","author":"L Pierro","year":"2012","unstructured":"Pierro L, Gagliardi M, Iuliano L, Ambrosi A, Bandello F. Retinal nerve fiber layer thickness reproducibility using seven different OCT instruments. Investig Ophthalmol Vis Sci. 2012;53:5912 https:\/\/doi.org\/10.1167\/iovs.11-8644.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4823_CR11","doi-asserted-by":"publisher","unstructured":"Lowe MC, Berman G, Labella \u00c1lvarez F, Shah P, Mollan SP. How to diagnose papilloedema. Pract Neurol. 2026;26(4):319\u201330. https:\/\/doi.org\/10.1136\/pn-2025-004784.","DOI":"10.1136\/pn-2025-004784"},{"key":"4823_CR12","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1212\/WNL.0b013e3182a55f17","volume":"81","author":"DI Friedman","year":"2013","unstructured":"Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology. 2013;81:1159\u201365. https:\/\/doi.org\/10.1212\/WNL.0b013e3182a55f17.","journal-title":"Neurology"},{"key":"4823_CR13","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1136\/jnnp-2017-317440","volume":"89","author":"SP Mollan","year":"2018","unstructured":"Mollan SP, Davies B, Silver NC, Shaw S, Mallucci CL, Wakerley BR, et al. Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry. 2018;89:1088\u2013100. https:\/\/doi.org\/10.1136\/jnnp-2017-317440.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"4823_CR14","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/s41433-019-0359-5","volume":"33","author":"RJ Blanch","year":"2019","unstructured":"Blanch RJ, Vasseneix C, Liczkowski A, Yiangou A, Aojula A, Micieli JA, et al. Differing presenting features of idiopathic intracranial hypertension in the UK and US. Eye. 2019;33:1014\u20139. https:\/\/doi.org\/10.1038\/s41433-019-0359-5.","journal-title":"Eye"},{"key":"4823_CR15","doi-asserted-by":"publisher","unstructured":"Thaller M, Homer V, Mollan SP, Sinclair AJ. Disease course and long-term outcomes in pregnant women with idiopathic intracranial hypertension: the IIH Prospective Maternal Health Study. Neurology. 2023;100. https:\/\/doi.org\/10.1212\/WNL.0000000000206854.","DOI":"10.1212\/WNL.0000000000206854"},{"key":"4823_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1212\/WNL.0000000000012125","volume":"97","author":"A Aytulun","year":"2021","unstructured":"Aytulun A, Cruz-Herranz A, Aktas O, Balcer LJ, Balk L, Barboni P, et al. APOSTEL 2.0 recommendations for reporting quantitative optical coherence tomography studies. Neurology. 2021;97:68\u201379. https:\/\/doi.org\/10.1212\/WNL.0000000000012125.","journal-title":"Neurology"},{"key":"4823_CR17","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1097\/WNO.0000000000001446","volume":"41","author":"SP Mollan","year":"2021","unstructured":"Mollan SP, Homer V, Gates S, Brock K, Sinclair AJ. One eye or two: statistical considerations in ophthalmology with a focus on interventional clinical trials. J Neuroophthalmol. 2021;41:421\u20133. https:\/\/doi.org\/10.1097\/WNO.0000000000001446.","journal-title":"J Neuroophthalmol"},{"key":"4823_CR18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","volume":"15","author":"TK Koo","year":"2016","unstructured":"Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 2016;15:155\u201363. https:\/\/doi.org\/10.1016\/j.jcm.2016.02.012.","journal-title":"J Chiropr Med"},{"key":"4823_CR19","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1213\/ANE.0000000000002864","volume":"126","author":"P Schober","year":"2018","unstructured":"Schober P, Boer C, Schwarte LA. Correlation coefficients: appropriate use and interpretation. Anesth Analg. 2018;126:1763\u20138. https:\/\/doi.org\/10.1213\/ANE.0000000000002864.","journal-title":"Anesth Analg"},{"key":"4823_CR20","doi-asserted-by":"publisher","unstructured":"Cohen, J. Statistical power analysis for the behavioral sciences. Routledge, 2013. Available from: https:\/\/doi.org\/10.4324\/9780203771587.","DOI":"10.4324\/9780203771587"},{"key":"4823_CR21","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.ajo.2010.06.024","volume":"150","author":"LK Seibold","year":"2010","unstructured":"Seibold LK, Mandava N, Kahook MY. Comparison of retinal nerve fiber layer thickness in normal eyes using time-domain and spectral-domain optical coherence tomography. Am J Ophthalmol. 2010;150:807\u2013814.e1. https:\/\/doi.org\/10.1016\/j.ajo.2010.06.024.","journal-title":"Am J Ophthalmol"},{"key":"4823_CR22","doi-asserted-by":"publisher","first-page":"E652","DOI":"10.1097\/OPX.0b013e318238c34e","volume":"89","author":"NB Patel","year":"2012","unstructured":"Patel NB, Wheat JL, Rodriguez A, Tran V, Harwerth RS. Agreement between retinal nerve fiber layer measures from Spectralis and Cirrus spectral domain OCT. Optom Vis Sci. 2012;89:E652\u201366. https:\/\/doi.org\/10.1097\/OPX.0b013e318238c34e.","journal-title":"Optom Vis Sci"},{"key":"4823_CR23","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231197118","volume":"43","author":"SP Mollan","year":"2023","unstructured":"Mollan SP, Fraser CL, Digre KB, Diener HC, Lipton RB, Juhler M, et al. Guidelines of the International Headache Society for Controlled Clinical Trials in Idiopathic Intracranial Hypertension. Cephalalgia. 2023;43:03331024231197118. https:\/\/doi.org\/10.1177\/03331024231197118.","journal-title":"Cephalalgia"},{"key":"4823_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-017-0652-7","volume":"17","author":"A Aojula","year":"2017","unstructured":"Aojula A, Mollan SP, Horsburgh J, Yiangou A, Markey KA, Mitchell JL, et al. Segmentation error in spectral domain optical coherence tomography measures of the retinal nerve fibre layer thickness in idiopathic intracranial hypertension. BMC Ophthalmol. 2017;17:257. https:\/\/doi.org\/10.1186\/s12886-017-0652-7.","journal-title":"BMC Ophthalmol"},{"key":"4823_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/WNO.0000000000002442","volume":"46","author":"SP Mollan","year":"2026","unstructured":"Mollan SP, Kulniwatcharoen P, Rao A, Berman G. Comment: clinical and imaging characteristics of uveitic optic disc edema. J Neuro-Ophthalmol J North Am Neuro-Ophthalmol Soc. 2026;46:145\u20137. https:\/\/doi.org\/10.1097\/WNO.0000000000002442.","journal-title":"J Neuro-Ophthalmol J North Am Neuro-Ophthalmol Soc"},{"key":"4823_CR26","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/pn-2025-004728","volume":"26","author":"SP Mollan","year":"2026","unstructured":"Mollan SP, Tsermoulas G, Berman G, Toma AK, Fergus R, White P, et al. Stenting versus shunting in sight-threatening idiopathic intracranial hypertension: genuine equipoise. Pr Neurol. 2026;26:142\u20135. https:\/\/doi.org\/10.1136\/pn-2025-004728.","journal-title":"Pr Neurol"},{"key":"4823_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuchi.2025.101754","volume":"72","author":"G Tsermoulas","year":"2026","unstructured":"Tsermoulas G, Gikas N, Sinclair AJ, Mollan SP, Berman G. Comment on \u201cSurgical versus endovascular treatment for idiopathic intracranial hypertension. Neurochirurgie. 2026;72:101754. https:\/\/doi.org\/10.1016\/j.neuchi.2025.101754.","journal-title":"Neurochirurgie"},{"key":"4823_CR28","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/IJG.0b013e3182071cdd","volume":"21","author":"BB Tan","year":"2012","unstructured":"Tan BB, Natividad M, Chua KC, Yip LW. Comparison of Retinal nerve fiber layer measurements between 2 spectral domain OCT instruments. J Glaucoma. 2012;21:266\u201373. https:\/\/doi.org\/10.1097\/IJG.0b013e3182071cdd.","journal-title":"J Glaucoma"},{"key":"4823_CR29","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.4103\/0301-4738.149136","volume":"62","author":"S Bassi","year":"2014","unstructured":"Bassi S, Mohana K. Optical coherence tomography in papilledema and pseudopapilledema with and without optic nerve head drusen. Indian J Ophthalmol. 2014;62:1146 https:\/\/doi.org\/10.4103\/0301-4738.149136.","journal-title":"Indian J Ophthalmol"},{"key":"4823_CR30","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/WNO.0000000000001569","volume":"42","author":"P Mallory","year":"2022","unstructured":"Mallory P, Wagley S, Chen J, McClelland CM, Downie PA, Lindgren B, et al. Ganglion cell layer thickness variance using SPECTRALIS optical coherence tomography. J Neuroophthalmol. 2022;42:310\u20135. https:\/\/doi.org\/10.1097\/WNO.0000000000001569.","journal-title":"J Neuroophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04823-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04823-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04823-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:09:04Z","timestamp":1794413344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04823-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":30,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["4823"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04823-4","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"19 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ASJ and GT are supported by the NIHR\u2014NIHR131211\u2014 Intervention To Preserve Vision In Idiopathic Intracranial Hypertension: Evaluation Of Clinical Effectiveness And Cost Effectiveness. IIH Intervention Trial. AJS is supported by a grant for Biomedical Research. AJS has consulted for Novartis, AbbVie, Vertex and Orion Pharma and received speaker fees from Teva UK and Novartis on unrelated topics. SPM reports consultancy fees (Novo Nordisk); advisory board fees (Ocular Therapeutix, Domp\u00e9); speaker fees (Teva, AbbVie); Travel (AbbVie, EssilorLuxottica, European Alliance of Associations for Rheumatology); Receipt of equipment (Heidelberg Engineering). SPM is a section editor at Eye. AY is funded by the Association of British Neurologists and Guarantors of the Brain for a 3-year Clinical Research Training Fellowship (2021-2024). NC was employed by University Hospitals Birmingham NHS Foundation Trust at the time of data collection and analysis. Authors declare no other financial relationships with any organisations that might have an interest in the submitted work, and no other relationships or activities that could appear to have influenced the submitted work.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}